CONMED Corporation (NYSE:CNMD) Receives Average Recommendation of “Reduce” from Brokerages

CONMED Corporation (NYSE:CNMD) has been given a consensus rating of “Reduce” by the eight ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $41.40.

A number of brokerages recently issued reports on CNMD. Weiss Ratings reissued a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. Wells Fargo & Company lifted their price objective on CONMED from $39.00 to $46.00 and gave the company an “equal weight” rating in a research note on Thursday. Needham & Company LLC reissued a “hold” rating on shares of CONMED in a report on Monday, July 13th. Zacks Research cut CONMED from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, BMO Capital Markets assumed coverage on CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target for the company.

Institutional Trading of CONMED

Institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in CONMED during the 4th quarter valued at about $26,000. Kelleher Financial Advisors bought a new position in shares of CONMED in the third quarter worth approximately $28,000. Aster Capital Management DIFC Ltd lifted its stake in shares of CONMED by 409.2% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock worth $29,000 after buying an additional 581 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of CONMED by 210.8% during the second quarter. Versant Capital Management Inc now owns 1,125 shares of the company’s stock valued at $37,000 after buying an additional 763 shares during the last quarter. Finally, Quarry LP grew its holdings in shares of CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after buying an additional 617 shares during the last quarter.

CONMED Stock Up 8.9%

Shares of NYSE:CNMD opened at $47.04 on Friday. The firm has a market capitalization of $1.42 billion, a P/E ratio of 25.43, a P/E/G ratio of 3.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. The stock has a 50 day moving average price of $37.09 and a 200-day moving average price of $38.42. CONMED has a 52-week low of $31.44 and a 52-week high of $56.63.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.28. CONMED had a return on equity of 14.38% and a net margin of 4.12%.The company had revenue of $343.49 million for the quarter, compared to analyst estimates of $337.60 million. During the same period in the previous year, the company posted $1.15 earnings per share. The firm’s revenue was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities research analysts anticipate that CONMED will post 4.38 EPS for the current fiscal year.

CONMED News Summary

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Quarterly earnings beat expectations. CONMED reported second-quarter EPS of $1.38, well above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million consensus forecast. CONMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Management now expects 2026 adjusted EPS of $4.48-$4.60, compared with the roughly $4.37 analyst consensus. Margin expansion, solid international sales and 6% organic sales growth excluding discontinued GI product offerings supported the improved outlook. CONMED Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Analysts increased their price targets. Wells Fargo raised its target to $46 from $39, while Piper Sandler increased its target to $45 from $39, reflecting greater confidence following the earnings report.
• Neutral Sentiment: Reported revenue growth remains limited. Sales increased only 0.3% year over year to $343.5 million, or declined 0.5% on a constant-currency basis, although underlying organic growth was stronger after excluding strategic GI product exits. CONMED Q2 Earnings and Revenues Top Estimates
• Negative Sentiment: Valuation and analyst ratings could limit further gains. Piper Sandler reaffirmed a “neutral” rating and Wells Fargo maintained “equal weight.” Their $45 and $46 targets are below the stock’s recent trading level, signaling that analysts view much of the earnings optimism as already reflected in CNMD’s valuation.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.